- Home
- BRBR vs AAPG Comparison
BRBR vs AAPG Comparison
Compare BRBR & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRBR | AAPG |
|---|---|---|
| Founded | 2019 | 2009 |
| Country | United States | China |
| Employees | N/A | 767 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | BRBR | AAPG |
|---|---|---|
| Price | $9.76 | $21.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 5 |
| Target Price | $36.63 | ★ $48.40 |
| AVG Volume (30 Days) | ★ 4.7M | 2.0K |
| Earning Date | 05-05-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $2,316,600,000.00 | N/A |
| Revenue This Year | $6.28 | $290.34 |
| Revenue Next Year | $5.81 | N/A |
| P/E Ratio | $15.88 | ★ N/A |
| Revenue Growth | ★ 16.05 | N/A |
| 52 Week Low | $9.22 | $20.11 |
| 52 Week High | $67.00 | $48.45 |
Technical Indicators
Market Signals| Indicator | BRBR | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 22.71 | 40.77 |
| Support Level | N/A | $21.20 |
| Resistance Level | $18.51 | $25.23 |
| Average True Range (ATR) | 1.01 | 0.50 |
| MACD | -0.75 | -0.24 |
| Stochastic Oscillator | 5.90 | 15.44 |
Price Performance
Historical ComparisonAbout BRBR BellRing Brands Inc.
BellRing Brands Inc is a United States-based company engaged in providing nutrition-related products. Its brands, Premier Protein, Dymatize, and PowerBar provides various products including ready-to-drink protein shakes, powders and nutrition bars. The company's products are distributed through a diverse network of channel including club, food, drug and mass, eCommerce, convenience and specialty.
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.